Researchers provide a conceptual overview of liver vasomics, including the classification of vascular phenotypes in the liver ...

THE effect of increased intra-abdominal pressure due to ascites upon portal and systemic hemodynamics has not been directly documented although the hemodynamics of ascitic cirrhotic patients have ...

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and ...

Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular carcinoma (HCC) development.

Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in ...

They were written in June 1998 and have been corrected and agreed upon by the members of the Liver Section. The nature of variceal haemorrhage in cirrhotic patients with its complex range of ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q4 2024 Earnings Call Transcript March 6, 2025 Atea Pharmaceuticals, Inc. misses on ...

Purpose: To establish a threshold value of liver elasticity for the prediction of esophageal varices in compensated cirrhotics. Methodology: retrospective and analytical study carried out in ...

Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular ...

Data analyses from the Phase 2b ENLIVEN trial highlighting the potential anti-fibrotic effects and the potential utility of non-invasive tests correlating with histological endpoints were presented at ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral ...